Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.45 |
| ▸ | FABP7 | O15540 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28659758 | 1.00 | FABP5 (0.45) | FABP5FABP7KMT2ACASP3EPHX2 | |
| SCHEMBL524832 | 0.98 | FABP5 (0.44) | FABP5FABP7KMT2ACASP3EPHX2 | |
| SCHEMBL6013918 | 0.98 | FABP5 (0.44) | FABP5FABP7KMT2ACASP3EPHX2 | |
| SCHEMBL11902423 | 0.96 | FABP5 (0.46) | FABP5FABP7KMT2ACASP3EPHX2 | |
| SCHEMBL20681006 | 0.96 | FABP5 (0.46) | FABP5FABP7KMT2ACASP3EPHX2 | |
| SCHEMBL4736280 | 0.87 | KMT2A (0.40) | FABP5FABP7KMT2ACASP3EPHX2 | |
| SCHEMBL4736278 | 0.87 | KMT2A (0.40) | FABP5FABP7KMT2ACASP3EPHX2 | |
| SCHEMBL29913804 | 0.83 | FABP5 (0.47) | FABP5FABP7KMT2ACASP3EPHX2 | |
| SCHEMBL120596 | 0.82 | FABP5 (0.46) | FABP5FABP7KMT2ACASP3EPHX2 | |
| SCHEMBL16095352 | 0.82 | FABP5 (0.46) | FABP5FABP7KMT2ACASP3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080161254-A1 | HCV INHIBITORS | VIROBAY, INC. (US) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161254-A1 | HCV INHIBITORS | HAVCR2, ZC3HAV1, EIF2AK2 | FABP5 2736/4885FABP7 4573/4885KMT2A 4134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.